UNIVERSITY OF SOUTH FLORIDA

Dr. Tiago Biachi highlights biosimilars' role in making GI cancer care sustainable by reducing costs and improving access. He stresses the need for clinicians to consider treatment costs and advocates for policies facilitating biosimilar development to combat financial toxicity and ensure equitable care.

2024 saw FDA approvals for needle-free pediatric treatments: epinephrine nasal spray (neffy) for anaphylaxis and FluMist for influenza, addressing needle phobia and improving vaccine administration.

Top hospitals in North America, including University of Minnesota, Toronto Western Hospital, UCSF Medical Center, Kaizen Brain Center, and University of South Florida, are conducting clinical trials on trigeminal neuralgia, aiming to improve treatment and quality of life for patients suffering from this severe facial pain condition.

The Transdermal Drug Delivery Pipeline Report, 2024 Update, offers comprehensive insights into pipeline products, development stages, clinical trials, and key companies shaping the transdermal drug delivery market.

Tampa General Hospital and USF College of Nursing secured $1,000,000 to enhance nursing education in Florida, aiming to graduate over 450 undergraduate and 260 advanced practice nurses annually by 2028. The funding supports scholarships, faculty recruitment, and simulation centers, addressing the state's nursing shortage and improving healthcare quality.

Five Florida nonprofits join California and Spain orgs to launch The Continuum, a $13.9M NOAA-funded initiative to accelerate BlueTech innovation for sustainable ocean economy growth by 2028.

A new study links an imbalance of omega-6 to omega-3 fatty acids, prevalent in Western diets high in ultraprocessed foods, to increased colorectal cancer risk. Omega-3s, found in fatty fish and certain seeds, help fight inflammation and tumors, but their effectiveness is hindered by excessive omega-6s. Experts recommend boosting omega-3 intake to counteract the negative impact of omega-6s.

The University of South Florida achieved a record $738 million in research funding in FY 2024, up 7% from the previous year and 35% since 2022. Over half of the funding comes from federal agencies, with NIH providing $227 million, and the Department of Defense increasing its funding by 73% to $36 million. USF aims to reach $1 billion in annual research funding.

Opus Genetics will host a virtual KOL event on Dec 11, 2024, to discuss 6-month efficacy and safety data on OPGx-LCA5, an AAV-based gene therapy for LCA5-associated IRD. Presenters include Jean Bennett, Tomas Aleman, Christine Kay, and Arshad Khanani, who will highlight the unmet need, development steps, and therapeutic potential. A live Q&A will follow.

BostonGene presents 12 abstracts at the 66th ASH Annual Meeting, highlighting AI-driven innovations in molecular and immunoprofiling for advancing cancer therapies.